Oppenheimer analyst Suraj Kalia maintained a Sell rating on Intuitive Surgical (NASDAQ:ISRG) on Wednesday, setting a price target of $410, which is approximately 48.39% below the present share price of $794.47.
Kalia expects Intuitive Surgical to post earnings per share (EPS) of $3.11 for the second quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Moderate Buy rating of shares in Intuitive Surgical, with an average price target of $780.14.
The analysts price targets range from a high of $879 to a low of $410.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $1.33 billion and a net profit of $415.8 million. The company's market cap is $94.05 billion.
According to TipRanks.com, Oppenheimer analyst Suraj Kalia is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 7.6% and a 55.68% success rate.
Intuitive Surgical, Inc. manufactures and develops robotic-assisted products, most notably with the da Vinci surgical system and related instruments and accessories, to improve clinical outcomes of patients through minimally invasive surgery. Its products include Da Vinci and Ion. The company was founded in 1995 and is headquartered in Sunnyvale, California.